Arantes-Oliveira, NunoGordeev, Denise2025-07-312025-01-302024-12-17http://hdl.handle.net/10362/185808Within the "Building Companies Based on Science" field lab, this thesis focuses on creating BioVantage, a startup leveraging state-of-the-art organ-on-chip (OoC) technology to transform preclinical drug development. Anchored by a licensed neuromuscular junction-on-chip (NMJ OoC), BioVantage will initially specialize in neuromuscular diseases while exploring future applications for heart- and liver-OoC. By integrating artificial intelligence in combination with the OoC technology, our venture not only enhances the cost- and time-effectiveness and accuracy of drug discovery, but also significantly reduces the reliance on animal testing. In this report we detail a strategic business plan for BioVantage, positioning it as an ethical and innovative partner in advancing preclinical drug research while redefining industry standards.engAmyotrophic lateral sclerosisAnimal testingArtificial IntelligenceContracted research organizationLambert-Eaton Myasthenic SyndromeMyasthenia gravisNeuromuscular diseasesOrgan-on-a-chipScience-based entrepreneurshipmaster thesis203959710